Don t gamble on your HERD S health.

Don t gamble on your HERD S health.

Boehringer Ingelheim Vetmedica, Inc. is a familyowned company that strives to deliver high-quality, innovative vaccines to the cattle industry. The Pyramid vaccine line is an example of that dedication. The Pyramid vaccines ensure your herd is protected against respiratory diseases. Several field trials have been done to test the vaccine. The studies show that calves only need a single dose of Pyramid for protection against the five key virus antigens that contribute to bovine respiratory disease (BRD) including bovine respiratory syncytial virus (BRSV). The Pyramid line of vaccines: Contains up to two BVD strains, which were selected for broad BVD protection: Singer Type 1 and 5912 Type 2 Is available in a convenient combination containing a five-way virus + M. haemolytica Is formulated with a MetaStim adjuvant system that helps maximize the animal s response to the vaccine for greater protection Is Beef Quality Assurance (BQA) compliant low 2 ml, sub-q dose. K = Killed Vaccine M = Modified-Live Vaccine Effects of Viral Vaccine on Health Parameters. (LS Means) IBR PI 3 BVD Type 1 BVD Type 2 BRSV Lepto 5 M. haemolytica Lepto pomona/ Lepto hardjo Pyramid 2 + Type 2 BVD M M M Pyramid 2 + Type 2/LPH M M M K Pyramid 4 M M M M Pyramid 5 M M M M M Pyramid 5 + Presponse SQ M M M M M K Pyramid 10 M M M M M K Pyramid IBR M Pyramid IBR/LPH M K Pyramid Vaccines Put to the Test Effect of Initial Respiratory Viral Vaccination Treatment on Feedlot Performance, Health and Carcass Characteristics of Auction-Market Derived Light-Weight Feeder Steers. (Technical Bulletin BIVI L0366T) (Bryant. The Bovine Practitioner. 42.1. 98 103) This study compares the effects of three initial respiratory viral vaccines on performance, health and carcass quality of lightweight, auction-market derived steers fed in a commercial feedlot setting. The three viral vaccines compared were: Pyramid 5 Bovi-Shield Gold 5 Bovi-Shield Gold IBR-BVD. Pyramid 5 Bovi-Shield Gold 5 Bovi-Shield Gold IBR-BVD Temp. at first pull, F 105.0 105.0 105.0 0.05 0.65 First pull BRD causes, c % 40.83 a 45.83 b 44.17 ab 0.09 Relapse, d % 14.92 a 19.09 b 18.53 b 0.04 Treats Non-BRD causes, % 2.76 3.67 2.57 0.30 Mortality BRD causes, % 3.08 3.95 4.31 0.31 Mortality All causes, % 4.51 5.88 6.34 0.19 Railer BRD causes, % 0.47 a 1.59 b 1.59 b 0.06 Railer All causes, % 1.50 2.16 2.34 0.37 a,b Means in the same row with different superscripts differ (P < 0.10). c Cattle that were pulled and treated for the first time for BRD-related diagnosis. d Cattle that were pulled and treated again regardless of location after already being treated for BRD-related ailments. An animal that relapsed more than one time was only counted once. Î ÎThe Pyramid 5 calves had 11% lower (40.83% vs. 45.83%; P = 0.09) incidence of BRD first pulls than the Bovi-Shield Gold 5 cattle and tended to have lower incidence of BRD first pulls than Bovi-Shield Gold IBR-BVD cattle. Î ÎAdditionally, the Pyramid 5 cattle had 22% and 19% lower relapse incidence than the Bovi-Shield Gold 5 and Bovi-Shield Gold IBR-BVD cattle, respectively (14.92% vs. 19.09% and 18.53%; P = 0.04), and numerically lower mortality than the other treatments. SE P-Value

Efficacy of Pyramid 5 in Calves with Maternal Antibodies Against a Virulent BVDV Type 2 Challenge Seven Months Following Vaccination. (Tech Bulletin BIVI L0495T) This trial was conducted to determine if young calves with BVD maternal antibody that were vaccinated with Pyramid 5 would be protected from BVD challenge after the maternal antibody had waned. The calves were divided into three groups: Group 1 calves were the negative controls (fed milk replacer only); Groups 2 and 3 were given pooled colostrum; Group 2 calves were vaccinated with Pyramid 5 at an average of 4.5 weeks of age; and Group 3 calves served as the maternal antibody positive controls and were not vaccinated. All were challenged on day 21. Survival Rates (%) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 14 Days Post Challenge: Pounds Gained/Lost 70 60 50 40 30 20 10 0 10 20 30 40 50 60 70 Average Weight Change 21 Days Post Challenge: Pounds Gained/Lost 70 60 50 40 30 20 10 0 10 20 30 40 50 60 70 Average Weight Change Negative Control Pyramid Positive Control Average Weight Change Î ÎTwo of the six calves in Group 1 died; none of the eight calves in Group 2 died; and four of the eight positive-control calves in Group 3 died or required euthanasia. A laboratory at South Dakota State University confirmed all six calves that died were infected with BVDV. Î ÎCalves in Group 2 gained weight at 14 and 21 days post challenge (DPC), while Groups 1 and 3 lost weight during 14 and 21 DPC. Î ÎIn this study, one dose of an adjuvanted MLV BVDV vaccine (Pyramid 5) administered in the presence of BVDV maternal antibodies was able to significantly reduce clinical signs of severe BVD when challenged seven months following vaccination. IBR Challenge of Pyramid 10 (Tech Bulletin FDP L0496T) A challenge study provided IBR serological data and challenge protection data for the Pyramid line of vaccines. In the study, calves vaccinated with Pyramid 10 were challenged 167 days following vaccination, and monitored for virus shedding, fever and other clinical disease signs. Mean Days Post-Challenge Virus Shedding Vaccinates 5.0 5.2 5.4 5.6 5.8 6.0 6.2 6.4 6.6 6.8 7.0 Control Results: The control group of calves remained sero-negative to IBR prior to challenge, but most of the vaccinated calves produced a measurable neutralizing antibody response following vaccination. Following the disease challenge, the vaccinated calves demonstrated an anamnestic antibody response to IBR. The strong antibody response shown by the vaccinated calves following the challenge makes these animals more likely to eliminate the infection and recover. Î ÎSignificant differences between treatment and control groups with regard to clinical signs of disease (e.g., mucopurulent discharge) (P < 0.05) Î ÎViral shedding was reduced (P < 0.10) and vaccinates demonstrated a significant reduction in fever (P < 0.10) compared to the control calves. Pyramid 10 BRSV Challenge Trial (Tech Bulletin FDP L0519T) A trial was conducted with 28 calves to evaluate Pyramid 10 efficacy versus a severe BRSV challenge. In the study, 14 calves were vaccinated with Pyramid 10, and 14 calves served as controls. All 28 calves were challenged with BRSV 21 days following the vaccination date, confined in a 24-foot stock trailer, and transported 60 miles. Calves were monitored for eight days post challenge, and then the lungs were scored postmortem for lesions consistent with BRSV infection.

Negative Control Pyramid 10 Survival Rates (%) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Pyramid 10 Visual Score of Lung Tissue Affected (%) Negative Control 0% 10% 20% 30% 40% 50% Pyramid 10 Digital Score of Lung Tissue Affected (%) Negative Control 0% 10% 20% 30% 40% 50% Î ÎRespiration rates can be a function of lung health or disease. After the BRSV challenge, respiration rates in control calves increased by an average of 28.8 breaths per minute (bpm) while rates in the Pyramid 10 vaccinated calves only increased 18.5 bpm. Overall, control calves had a significant (P > 0.05) increase of 10.3 bpm compared to Pyramid 10 vaccinates. Î ÎPyramid 10 vaccinated calves maintained better blood oxygenation levels, and demonstrated lower respiratory rates than control calves (P < 0.05) following the BRSV challenge. Î ÎThis study demonstrated that one dose of Pyramid 10 was effective to protect against disease caused by BRSV. Virulent BVDV Type 2 Challenge of BVDV-Naïve and BVDV Maternal Antibody Positive Neonatal Calves Vaccinated at Five Weeks Old with Pyramid 5. (Tech Bulletin BIVI L0340T) The efficacy of Pyramid 5 was challenged 3.5 months post vaccination against a virulent Type 2 BVD virus in dairy bull calves. The calves were divided into three groups based on serum antibody titers for BVDV. BVD-naïve and BVD antibody positive calves were vaccinated once with Pyramid 5, and along with antibody-negative, unvaccinated controls, were challenged intranasally with virulent Type 2 BVD. Calves were monitored for clinical signs of the disease, and blood samples were taken. Figure 1a. Clinical Scores Following Challenge with BVDV Type 2 at 104 Days After Vaccination with Pyramid 5 8 Total Clinical Score Value 7 6 5 4 3 2 1 0 3 2 1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Study Day Post Challenge Figure 1b. Clinical Scores Following Challenge with BVDV Type 2 at 104 Days After Vaccination with Pyramid 5 Total Clinical Score Value 0 10 20 30 40 50 60 70 Total Clinical Score for Day 3 to Day 14 Post Challenge Figure 2. BVDV Virus Isolation Following Challenge with BVDV Type 2 at 104 Days Post Vaccination with Pyramid 5 Days Post Challenge -1 1 3 5 7 9 11 13 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Percentage of Calves Shedding Virus Control Pyramid 5 / BVDV Ab Pyramid 5 / BVDV Ab+ Results: The control group calves exhibited significantly higher average clinical scores compared to either vaccinated group, beginning four days post challenge through the 14-day observation period. The results are summarized in Figures 1a and 1b. During the trial, all vaccinates were protected against BVD disease and survived. Six of the seven control calves shed BVD from three days to 13 days of the trial, while vaccinates did not shed virus. Î ÎThe study demonstrates the strong, productive immune stimulation provided by Pyramid 5 against virulent viral challenge in neonatal calves, even in the face of the maternal-antibody titers present at the time of vaccination.

The MetaStim Advantage The Pyramid vaccine family incorporates the unique MetaStim adjuvant system to enhance the immune response and provide the protection against the key virus and bacterial antigens when your animals are challenged. Antigen Circulating antibodies neutralize the exposed antigen. Circulating antibodies The hidden antigen in Pyramid is NOT neutralized by circulating antibodies. The immune system metabolizes the complex, releasing the hidden antigen to provide further immune stimulation. Two BVD Strains Advantage Singer TYPE 1 5912 TYPE 2 N2 CA-1 CA-3 CA-34 CA-36 CA-39 CA-72 CA-78 CA-80 CA-82 BZ-1 BZ-2 BZ-3 BZ-4 BZ-14 BZ-15 BZ-19 BZ-23 BZ-24 BZ-25 BZ-26 BZ-29 BZ-30 BZ-32 BZ-33 BZ-34 BZ-35 BZ-52 BZ-53 BZ-55 BZ-60 BZ-61 BZ-70 BZ-71 BZ-73 BZ-77 BZ-79 BZ-81 CO-6 CO-7 CO-8 CO-14 Using the two strains in Pyramid, this panel demonstrated a wide range of reactive proteins covered by the vaccine 80 percent of the antibodies reacted. Contact your veterinarian or local Boehringer Ingelheim Vetmedica, Inc. representative for more information. Call 800-325-9167 or visit bi-vetmedica.com.

Express is a registered trademark of Boehringer Ingelheim Vetmedica, Inc. 2010 Boehringer Ingelheim Pyramid and Vetmedica, Presponse are Inc. registered BIVI 1290-5D trademarks of Boehringer Ingelheim Vetmedica, Inc. MetaStim is a registered trademark of Wyeth LLC and is used under license. Bovi-Shield Gold is a registered trademark of Pfizer Inc. 2011 Boehringer Ingelheim Vetmedica, Inc. BIVI 1580-5